Core Viewpoint - A groundbreaking oral nutritional supplement, "Dr. End PQQ Dihydroquercetin Compound Peptide Effervescent Tablets," developed by the Seiko Telomere Programming Laboratory in collaboration with Harvard Anti-Aging and Anti-Cancer Research Center, is set to launch globally in August 2025, marking a significant advancement in the field of immune modulation and anti-aging cancer prevention [1][7]. Group 1: Product Development and Technology - The product utilizes "Functional Modulation NK Cells" technology to precisely regulate the activity of endogenous NK cells, aiming to restore immune balance and address the decline in NK cell quantity and activity due to aging and environmental factors [3][5]. - The supplement is backed by multiple top-tier invention patents, with international patents in the anti-aging and anti-cancer fields already granted, establishing a strong technological barrier and global leadership [1][5]. Group 2: Clinical Trials and Efficacy - A clinical trial involving 586 participants aged 45-65 demonstrated a significant increase in endogenous NK cell quantity and activity, with an average improvement rate of 21.3% after 24 weeks of continuous use [5]. - The product's safety and reliability are enhanced as it activates the body's endogenous NK cells without external interference, contrasting with the risks associated with exogenous NK cell activation therapies [5][6]. Group 3: Market Launch and Global Impact - The product will be marketed globally by Seiko Pharmaceutical Technology (Jiangsu) Co., Ltd., through the "Dr. End Health Happy Mall," highlighting a milestone in the biopharmaceutical industry and a historic breakthrough in immune modulation and anti-aging cancer prevention [7]. - This launch is expected to inject significant momentum into global health and well-being, ushering in a new era of precise immune protection [7].

Core Viewpoint - The continuous implementation of centralized drug procurement in China is reshaping the pharmaceutical industry, pushing traditional companies towards efficiency, innovation, and international expansion to ensure sustainable development [1][2]. Group 1: Centralized Drug Procurement - The National Healthcare Security Administration has conducted the tenth batch of centralized drug procurement, involving 62 types of drugs, bringing the total to 435 since 2018 [1]. - Experts indicate that the normalization of centralized procurement is forcing traditional pharmaceutical companies to abandon simple expansion strategies and adapt to a more efficient and innovative operational model [1][2]. Group 2: Cost Control and Efficiency - Centralized procurement has significantly reduced drug prices by compressing the price margins in the distribution chain, compelling traditional companies to optimize costs and build a lean management system across the entire industry chain [2]. - Companies like Jiangsu Jibeier Pharmaceutical have implemented strict procurement management systems to control costs, while Health元药业 has integrated AI technology to enhance production efficiency and reduce risks [2]. Group 3: Research and Development - 博瑞医药 has increased its R&D investment in innovative drugs and inhalation formulations to 62.78% of total R&D spending, a year-on-year increase of 77.37% [3]. - The shift from scale expansion to lean survival is seen as a long-term strategic choice for traditional pharmaceutical companies, emphasizing the importance of genuine innovation for sustainable growth [3][4]. Group 4: Innovation and Market Position - Traditional pharmaceutical companies are increasingly focusing on developing innovative drugs and high-barrier generic drugs to transition from reliance on low-cost generics [4]. - 恒瑞医药 has invested 46 billion yuan in R&D since 2011, achieving significant milestones in innovative drug approvals and clinical trials [5]. Group 5: International Expansion - Chinese pharmaceutical companies are becoming key players in the global market, with over 90 licensing transactions completed in 2024, totaling over 50 billion USD [7]. - The trend of "going global" is driven by enhanced R&D capabilities and favorable external conditions, allowing companies to compete effectively on the international stage [7][8].

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3525.40 points, above the annual line, with a change of 0.43% [1] - The total trading volume of A-shares reached 987.43 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.51% - Ruisheng Technology (688090) with a deviation rate of 2.05% [1] Stocks with Significant Deviation Rates - The stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, trading at 76.99 yuan - Tongyi Co., Ltd.: 2.50% increase, trading at 16.00 yuan - Ruisheng Technology: 3.24% increase, trading at 35.10 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Qianjiang Motorcycle, Jiuquan Technology, and Huadian International, which have just reached the annual line [1]

Group 1 - The legal opinion letter confirms that the procedures for convening and holding the shareholders' meeting comply with the Company Law, Shareholders' Meeting Rules, and the company's articles of association [2][3][5] - The shareholders' meeting was scheduled for July 11, 2025, with a registration date of July 3, 2025, and utilized both a physical meeting and an online voting system [2][3] - A total of 1,213 shareholders participated in the online voting, representing 154,915,116 shares, which is 10.3561% of the total voting shares [3][4] Group 2 - The voting results showed that 152,045,883 shares were in favor of the proposals, accounting for 98.1478% of the valid votes cast [5] - Among minority investors, 12,045,883 shares voted in favor, representing 80.7629% of the valid votes from this group [5] - The legal opinion concludes that the meeting's procedures, participant qualifications, voting methods, and results are all valid and comply with relevant laws and regulations [5][6]

近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的福多司坦片（以下简称"该药品"）《药品注 册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：福多司坦片 受理号：CYHS2302051 证书编号：2025S02096 剂型：片剂 证券代码：600056 证券简称：中国医药 公告编号：临 2025-054 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 规格：0.2g 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）福多司坦片由日本三菱制药株式会社研制，于 2001 年 12 月在日本上 市。临床主要用于支气管哮喘、慢性喘息性支气管炎、支气管扩张、肺结核、尘 肺、慢性阻塞性肺气肿、非典型分枝杆菌 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-055 号 中国医药健康产业股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 11 日 (二)股东大会召开的地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,213 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 154,915,116 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 10.3561 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，由董事长杨光先生主持。本次会议的召集、召开、 表决方式符合有关法律、行政法规和《公司章程》的有关规 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 除本法律意见书特别说明外，若相关数据合计数与各分项数值之和不等于 100%系由四舍五入造成。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 道德规范及勤勉尽责精神，对公司提供的相关文件和有关事实进行了核查和验证， 1 现出具法律意见如下： 一． 本次股东大会的召集、召开程序 关于中国医药健康产业股份有限公司 2025 年第四次临时股东大会法律意见书 致：中国医药健康产业股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受中国医药健康产业股 份有限公司（以下简称"中国医药"或"公司"）的委托，指派律师出席了公司 2025 年第四次临时股东大会（以下简称"本次股东大会"）。本所依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等相关法律法规以及现行有效的《中国医药健康产 业股份有限公司章程》（以下简称"《公司章程》"）的规定，出具本法律意见 书。 ...

中国医药（600056）公告，下属全资子公司天方药业（600253）收到国家药监局核准签发的福多司坦片 《药品注册证书》。该药品主要用于呼吸道疾病的祛痰治疗，由日本三菱制药株式会社研制，于2001年 12月在日本上市。国家药监局于2023年8月受理注册申请，截至公告披露日，累计研发投入约1161万 元。国内已有5家生产企业获得该药品批件，2023年国内总销售额约为1.17亿元，2024年约为1.28亿元。 ...

Core Viewpoint - The Chinese pharmaceutical industry is experiencing positive changes driven by policy optimization and innovation, with a focus on internationalization and high-quality development [2][3]. Group 1: Industry Development - China's pharmaceutical industry has become a global leader in the production of active pharmaceutical ingredients (APIs) and small to medium-sized medical devices, playing an increasingly important role in the global pharmaceutical landscape [1][2]. - The industry is transitioning from exporting intermediates and APIs to a comprehensive export of innovative products, marking a significant shift in the internationalization of Chinese pharmaceuticals [2][3]. Group 2: Policy and Regulatory Environment - Recent reforms in drug and medical device regulation have enhanced the safety and effectiveness of products while stimulating innovation within the industry [4][5]. - The acceleration of drug review and approval processes, along with China's membership in the International Council for Harmonisation (ICH), has created a "fast track" for innovative drugs to enter international markets [2][3]. Group 3: Market Strategies and Internationalization - Companies are encouraged to adopt differentiated and refined market entry strategies by analyzing regional market characteristics, disease profiles, payment capabilities, and competitive landscapes [3][4]. - Successful case studies highlight the importance of collaboration, local production, and building partnerships to penetrate target markets effectively [5]. Group 4: Challenges and Future Directions - Despite the progress, the industry faces various internal and external challenges that require modernization of the regulatory system and governance capabilities to ensure high-quality development [3][5]. - The industry must maintain confidence and focus on enhancing innovation capabilities and quality control to navigate complex international environments and competition [5].